GlassScriptPhysician profile
Robert L Taddeo
NPI 1558358523
$863.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2021: $15.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $108.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.38 | 2019 | |
| Glaxosmithkline, LLC. | $90.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.63 | 2019 | |
| Amarin Pharma, INC. | $65.26 | 2019 | |
| Astellas Pharma US INC | $62.11 | 2019 | |
| Abbvie INC. | $58.09 | 2019-2021 | |
| Pfizer INC. | $52.37 | 2019 | |
| Bausch Health US, LLC | $36.88 | 2019 | |
| Amgen INC. | $35.07 | 2019 | |
| Daiichi Sankyo INC. | $31.91 | 2019 | |
| Novo Nordisk INC | $31.13 | 2019 | |
| Merck Sharp & Dohme LLC | $27.53 | 2019 | |
| Allergan, INC. | $22.25 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.31 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $12.89 | 2019 | |
| Sanofi Pasteur INC. | $12.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Taddeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.